European Drug Companies Taking Top 4 Ranking Positions by 2012 Finds EvaluatePharma's World Preview Report

Article ID: 542789

Released: 21-Jul-2008 2:35 PM EDT

Source Newsroom: EvaluatePharma

  • Share
  • Credit: EvaluatePharma

    Current research from EvaluatePharma shows European-based pharma companies will lead the pack in overall performance with Sanofi-Aventis (NYSE: SNY) taking the lead sales position with a projected $48 billion in 2012.

Newswise — EvaluatePharma® (, the web based analysis and intelligence service company for the pharma and biotech industry, released its first edition of the World Preview Report. This report showcases top-level analysis and insight into the expected performance of the global industry through 2012.

"The compound annual growth rate ("CAGR" ) of global prescription drug sales is expected to slowdown to 4.6% over the 2009 and 2012 period," said Jonathan de Pass, founder and CEO of EvaluatePharma. "Furthermore, our research shows European-based pharma companies will lead the pack in overall performance with Sanofi-Aventis (NYSE: SNY) taking the lead sales position with a projected $48 billion in 2012."

Based on EvaluatePharma's coverage of the world's leading five-hundred pharmaceutical and biotech companies, the World Preview Report highlights trends in prescription drugs sales, patent risk, R&D spending, global brand sales, and therapeutic performance. Included in the report is a brief review of 2007 performance. Some of the analysis highlights include:

"¢ Worldwide prescription drug sales total $753 billion in 2012 but growth rate slows to 4.6% CAGR between 2009 - 2012"¢ Sales at risk from patent expirations to top $120 billion in 2011/2012 "¢ European companies set to take "Top 4" ranking positions in 2012"¢ Biotechnology products to represent 44% of the "Top 100" global product sales in 2012"¢ Global pharmaceutical R&D spending (CAGR) up 5% to $148 billion by 2012"¢ Vaccines to record highest growth of major therapy categories 2012 "¢ 2007 potential new drug sales (NMEs) down 37% versus 2006 cohort of NMEs

To get your complimentary copy of the report, visit the company's website at

About EvaluatePharma®

EvaluatePharma delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. EvaluatePharma tracks all industry events that impact the sector, updates in real-time, and aggregates this cornucopia of information into one easy-to-use platform, providing an invaluable source for fund managers, analysts, and media covering the industry.

Since 1998 EvaluatePharma has been providing senior decision makers within the pharmaceutical industry with an essential service that models the sector from the viewpoint of the world's financial markets. EvaluatePharma's forward looking view of the market is hugely influential as it displays the consensus of expectations, which form company stock market valuations. The forecasts of equity analysts reveal their perspectives on individual company performance, industry trends, and the macro economic environment. EvaluatePharma has captured the consensus of equity analysts and seamlessly integrated them with the historic results, as reported by companies. From this comprehensive view of the industry, its past and expected future performance emerges and can be analyzed using EvaluatePharma. Analyses range from total market trends and therapeutic overviews to individual company performance and product progress.


Chat now!